Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
NCT06376045 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rocatinlimab
Study Locations (20)
California
- Kern Research Inc — Bakersfield
- Orso Health Inc — La Jolla
- Imax Clinical Trials — La Palma
- Antelope Valley Clinical Trials — Lancaster
- Downtown Los Angeles Research Center, Inc — Los Angeles
- NewportNativeMD, Inc — Newport Beach
- University of California Irvine — Orange
- Apex Clinical Research — San Diego
- Allergy and Asthma Clinical Research — Walnut Creek
- Allianz Research Institute Westminster — Westminster
Florida
- St Francis Medical Institute — Clearwater
- BioMed Research Institute — Miami
- Bright Research Center LLC — Miami
- Infinity Life Research Group — Tamarac
- Clinical Research Trials of Florida Inc — Tampa
Georgia
- AllerVie Clinical Research- Columbus — Columbus
Idaho
- Treasure Valley Medical Research — Boise
Illinois
- Sneeze, Wheeze, and Itch Associates, LLC — Normal
Kentucky
- Family Allergy and Asthma Research Institute — Louisville
Maryland
- Chesapeake Clinical Research Inc — White Marsh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2026-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06376045
The ClinicalTrials.gov registry entry for NCT06376045 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 266 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06376045 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06376045 about?
NCT06376045 is a clinical study titled "A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma". The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
What is the current status of trial NCT06376045?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2024-05-24. Estimated completion is 2026-12-11.
What conditions does trial NCT06376045 study?
This clinical trial studies the following conditions: Asthma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06376045?
The interventions under investigation include: Placebo (DRUG), Rocatinlimab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06376045?
This trial is sponsored by Amgen, which has 266 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06376045 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.